Cochrane Abstracts
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Chemotherapy, Radiotherapy and Combined Modality for Hodgkin's Disease, With Emphasis On Second Cancer Risk." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434829/all/Chemotherapy__radiotherapy_and_combined_modality_for_Hodgkin's_disease__with_emphasis_on_second_cancer_risk.
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434829/all/Chemotherapy__radiotherapy_and_combined_modality_for_Hodgkin's_disease__with_emphasis_on_second_cancer_risk. Accessed January 19, 2025.
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434829/all/Chemotherapy__radiotherapy_and_combined_modality_for_Hodgkin's_disease__with_emphasis_on_second_cancer_risk
Chemotherapy, Radiotherapy and Combined Modality for Hodgkin's Disease, With Emphasis On Second Cancer Risk [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434829/all/Chemotherapy__radiotherapy_and_combined_modality_for_Hodgkin's_disease__with_emphasis_on_second_cancer_risk.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk
ID - 434829
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434829/all/Chemotherapy__radiotherapy_and_combined_modality_for_Hodgkin's_disease__with_emphasis_on_second_cancer_risk
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
